Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Non-cash Items (2020 - 2022)

Rapid Micro Biosystems recorded quarterly Non-cash Items of $9.0 million in Q2 2022, down 43.27% quarter-over-quarter from $15.9 million in Q1 2022, and up 125.25% year-over-year from $4.0 million in Q2 2021.

Rapid Micro Biosystems' Non-cash Items history runs 3 years deep, the most recent figure standing at $9.0 million for Q2 2022.

  • In Q2 2022, Non-cash Items rose 125.25% year-over-year to $9.0 million; the TTM figure through Jun 2022 stood at $9.0 million (up 125.25% YoY), while the FY2021 annual figure was $31.0 million, up 626.62% from the prior year.
  • Non-cash Items came in at $9.0 million for Q2 2022 at Rapid Micro Biosystems, down from $15.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $31.0 million in Q4 2021 to a low of $2.1 million in Q3 2021.
  • A 3-year average of $11.1 million and a median of $6.6 million in 2020 frame the typical range for Non-cash Items.
  • Across the five-year window, Non-cash Items soared 626.62% in 2021 and soared 125.25% in 2022, its largest moves.
  • Rapid Micro Biosystems' Non-cash Items stood at $4.3 million in 2020, then jumped by 626.62% to $31.0 million in 2021, then slumped by 70.97% to $9.0 million in 2022.
  • According to Business Quant data, Non-cash Items over the past three periods registered $9.0 million, $15.9 million, and $31.0 million for Q2 2022, Q1 2022, and Q4 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Rapid Micro Biosystems 89.50 Mn 66.56 Mn 371,000.00

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 2.43 Mn
Jun 30, 2022 2.43 Mn
Mar 31, 2022 2.10 Mn
Mar 31, 2022 2.10 Mn
Dec 31, 2021 31.04 Mn
Dec 31, 2021 31.04 Mn
Sep 30, 2021 66.23 Mn
Sep 30, 2021 66.23 Mn
Jun 30, 2021 1.89 Mn
Jun 30, 2021 1.89 Mn
Dec 31, 2020 4.27 Mn
Dec 31, 2020 4.27 Mn